Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Novel transcript, antisense to DET1" (ENSG00000305611/LOC124903547) is currently annotated as a long non-coding RNA (lncRNA) that is transcribed antisense to the DET1 gene. Natural antisense transcripts (NATs) are a widespread class of RNAs found throughout eukaryotic genomes and can regulate the expression of their sense-strand counterparts via mechanisms such as transcriptional interference, RNA editing, or chromatin modification[3][1]. The specific biological function and disease relevance of this transcript remain uncharacterized, and it is not established as a therapeutic target. Its role is likely in modulating DET1 gene expression, but the details have not been experimentally defined in literature or major genomics repositories. This transcript is cataloged as a natural antisense RNA with no current evidence for therapeutic targeting or disease involvement; it is not a receptor, enzyme, or typical drug target class, and little functional information is available[3][1].
No characterized mechanism of action for this transcript as a drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to DET1 (ENSG00000305611).